A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

The purpose of this study is to estimate the proportion of participants fulfilling criteria for symptomatic remission following a transition to 12 months treatment with flexible-dose paliperidone palmitate 3 month formulation (PP3M) in participants with schizophrenia previously adequately treated with paliperidone palmitate 1 month formulation (PP1M) for at least 4 months.

本研究旨在评估既往接受至少4个月棕榈酸帕利哌酮1个月剂型（paliperidone palmitate 1 month formulation，PP1M）充分治疗的精神分裂症患者，在转为采用灵活剂量棕榈酸帕利哌酮3个月剂型（paliperidone palmitate 3 month formulation，PP3M）接受12个月治疗后，符合症状缓解标准的受试者占比。